Gene Therapy Shows Promise For Hemophilia, But Could Be Most Expensive U.S. Drug Ever

Biomarin Pharmaceutical, a California company that makes what could become the first gene therapy for hemophilia, says its drug

The first gene therapy for hemophilia could be approved by the FDA within six months, according to the drugmaker, raising hopes among families. But the drug’s price could be $3 million per patient.

(Image credit: Maciej Frolow/Getty Images)

Read the full post on Health Care : NPR